# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises the price target from $20 t...
Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to...
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to $18.
Cellebrite DI (NASDAQ:CLBT) sees Q3 sales of $121.000 million-$126.000 million vs $124.357 million analyst estimate.
Cellebrite DI (NASDAQ:CLBT) lowers FY2025 sales outlook from $470.000 million-$485.000 million to $465.000 million-$475.000 mil...
Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 b...